Correlation Between Lyra Therapeutics and Inhibrx

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Lyra Therapeutics and Inhibrx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lyra Therapeutics and Inhibrx into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lyra Therapeutics and Inhibrx, you can compare the effects of market volatilities on Lyra Therapeutics and Inhibrx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lyra Therapeutics with a short position of Inhibrx. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lyra Therapeutics and Inhibrx.

Diversification Opportunities for Lyra Therapeutics and Inhibrx

0.82
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Lyra and Inhibrx is 0.82. Overlapping area represents the amount of risk that can be diversified away by holding Lyra Therapeutics and Inhibrx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibrx and Lyra Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lyra Therapeutics are associated (or correlated) with Inhibrx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibrx has no effect on the direction of Lyra Therapeutics i.e., Lyra Therapeutics and Inhibrx go up and down completely randomly.

Pair Corralation between Lyra Therapeutics and Inhibrx

Given the investment horizon of 90 days Lyra Therapeutics is expected to under-perform the Inhibrx. In addition to that, Lyra Therapeutics is 2.48 times more volatile than Inhibrx. It trades about -0.11 of its total potential returns per unit of risk. Inhibrx is currently generating about -0.05 per unit of volatility. If you would invest  1,576  in Inhibrx on September 23, 2024 and sell it today you would lose (116.00) from holding Inhibrx or give up 7.36% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Lyra Therapeutics  vs.  Inhibrx

 Performance 
       Timeline  
Lyra Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Lyra Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Inhibrx 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Inhibrx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental drivers, Inhibrx is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Lyra Therapeutics and Inhibrx Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Lyra Therapeutics and Inhibrx

The main advantage of trading using opposite Lyra Therapeutics and Inhibrx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lyra Therapeutics position performs unexpectedly, Inhibrx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibrx will offset losses from the drop in Inhibrx's long position.
The idea behind Lyra Therapeutics and Inhibrx pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
CEOs Directory
Screen CEOs from public companies around the world
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Volatility Analysis
Get historical volatility and risk analysis based on latest market data